BIOVAXYS TECHNOLOGY CORP - BVAXF STOCK NEWS

BioVaxys Technology Corp (OTCQB: BVAXF) has announced significant study results for its DPX™ immune-educating delivery platform. The research, conducted with Dalhousie University, demonstrates that DPX outperforms traditional aqueous and emulsion-based antigen delivery systems in immune system activation. Key findings show that DPX maintains antigens at the injection site and drives active APC uptake over time. The platform demonstrated superior lymphocyte retention and significant immune cell infiltration within 2 days of injection. Notably, DPX showed activation of more critical T cell subset markers than oil emulsion systems and exhibited inherent immune-activating properties even without antigen cargo.

BioVaxys Technology Corp (CSE: BIOV, OTCQB: BVAXF) announces its participation in the upcoming Emerging Growth Conference on October 30th, 2024, at 9:40 AM EST. CEO James Passin will deliver a live, interactive presentation, providing an opportunity for shareholders and investors to engage directly with the company leadership.

The clinical-stage company, which develops immune-educating therapies using its DPX™ platform for cancers, infectious diseases, and immune disorders, welcomes questions from participants either in advance via Questions@EmergingGrowth.com or during the live event. For those unable to attend, an archived webcast will be available on EmergingGrowth.com and their YouTube channel.

BioVaxys Technology Corp. (CSE: BIOV, OTCQB: BVAXF) has engaged Dr. Rajkannan Rajagopalan as Advisor for developing and producing the Company's DPX™ formulations. Dr. Rajagopalan, with over 20 years of experience in nanoparticles formulation development, will assist with:

• Development of DPX formulations for the peanut allergy vaccine program with McMaster University
• Planned preclinical studies of DPX/mRNA vaccines
• Continued Phase 1 studies in oncology and infectious disease
• Expansion into new opportunities with DPX
• Support for current licensees using liposomes-based vaccine technology
• Establishing BioVaxys' non-GLP clinical supply facility for DPX formulations production

Additionally, Brittany Davison, a Chartered Professional Accountant, joins as an Advisor from the former IMV, Inc., where she served as Chief Accounting Officer and Acting Chief Financial Officer.

BioVaxys Technology Corp. (CSE: BIOV, OTCQB: BVAXF) announces CEO James Passin's upcoming presentation at the Life Sciences Investor Forum on September 19th, 2024. The live, interactive online event allows investors to engage directly with the company.

Recent highlights include:

• Acquisition of DPX™ immune educating platform technology assets
• Collaboration with AP Visionaries to develop food allergy treatments
• Potential product registrations from licensees Zoetis and SpayVac-for-Wildlife
• Advancement of DPX™ platform for infectious diseases

BioVaxys is developing novel immunotherapies for cancers, infectious diseases, and other immunological conditions using its DPX™ and HapTenix© platforms. The company's lead candidate, maveropepimut-S, is in Phase II trials for DLBCL and ovarian cancer.

BioVaxys Technology Corp. (BVAXF) has been invited to present at The Personalized Cancer Vaccine Summit in Boston, MA, from December 3-5, 2024. The presentation, titled "A Novel Delivery System for Personalized Peptide & mRNA Vaccines for More Targeted Therapies," will showcase new data on the company's DPX Immune Educating Platform.

Chief Medical Officer David Berd, MD, will present findings from recent in vivo studies conducted by researchers at UConn Health and The Ohio State University Comprehensive Cancer Center. The data suggests that DPX has a significant role in delivering tumor neoepitope vaccines that induce tumor rejection and may possess anti-tumor capacity on its own.

BioVaxys is continuing additional studies on DPX's potential in delivering tumor neoepitope vaccines and its anti-tumor capabilities.

BioVaxys Technology Corp. (BVAXF) highlights the potential of its DPX™ lipid-in-oil delivery platform for vaccines across multiple infectious diseases. Key findings include:

1) In a Phase 1 RSV study, 93% of subjects developed antigen-specific immune responses, with 100% maintaining immunity after one year in the 25μg dose group.

2) A DPX-based anthrax vaccine showed 100% immunity from a single injection in animal studies.

3) For influenza, DPX-rHA achieved higher antibody levels than standard Alum rHA vaccines and protected against multiple flu strains in preclinical studies.

BioVaxys is seeking partnerships to further develop these promising vaccine candidates targeting RSV, anthrax, influenza, and other infectious diseases.

BioVaxys Technology Corp. (CSE: BIOV, OTCQB: BVAXF) and SpayVac for Wildlife, Inc. have announced the completion of SpayVac's new research and production facility in Madison, Wisconsin. The facility will produce long-lasting, single-dose veterinary contraceptive vaccines using a patented liposome-based antigen delivery platform technology licensed from BioVaxys. These vaccines aim to address fertility control needs in wildlife, agricultural production animals, and aquaculture markets.

SpayVac relocated from the University of Victoria, British Columbia, to Madison with support from the BrightStar Wisconsin Foundation and angel investors. The new laboratory will enhance the company's ability to develop new vaccine formulations for various species. SpayVac plans to commercialize fertility control vaccines for deer, horses, and other animals, with regulatory approval filing expected in 2025 and subsequent commercial sales generating royalty revenue for BioVaxys.

BioVaxys Technology Corp. (OTCQB: BVAXF) has signed a binding Letter of Intent with AP Visionaries, Inc. to jointly develop a DPX™-based therapy for life-threatening food allergies, specifically peanut/tree nuts and eggs. The collaboration involves The Schroeder Allergy and Immunology Research Institute at McMaster University. BioVaxys will fund the study and retain intellectual property rights, while APVI will receive royalties and milestone payments.

The global peanut allergy treatment market is expected to reach USD 1.01 billion by 2030, growing at a CAGR of 11.82% from 2024 to 2030. Peanut allergies affect about 1.2% of the US population and 2.5% of children, with an estimated annual economic cost of $24.8 billion for food allergies in US children.

The DPX™ platform's flexibility and immune-educating capability offer potential advantages over current treatments, which often require frequent dosing and carry risks of anaphylaxis.

BioVaxys Technology Corp. (CSE: BIOV, OTCQB: BVAXF) has been issued U.S. Patent No. 12,042,537 by the USPTO for inducing an antibody immune response using a low dose volume delivery of a B-cell epitope formulated with DPX™. This proprietary lipid-based delivery platform allows for a robust and long-duration immune response. The technology enables delivery of less than 100 µl, packaging 5-50 µL of an antigen.

Potential applications include epitope-based vaccines for chronic hepatitis-B, influenza, and RSV. A previous Phase 1 study of DPX-RSV showed promising results, with 93% of participants maintaining antigen-specific immune responses after nine months. This patent issuance strengthens BioVaxys' position for further development and potential partnerships in epitope-based vaccine development.